{"generic":"Miconazole Nitrate","drugs":["Fungoid","Lotrimin AF","Micatin","Miconazole Nitrate","Monistat 1","Monistat 3","Monistat 7","Monistat Derm","Zeasorb-AF"],"mono":{"0":{"id":"374290-s-0","title":"Generic Names","mono":"Miconazole Nitrate"},"1":{"id":"374290-s-1","title":"Dosing and Indications","sub":{"0":{"id":"374290-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Candidal vulvovaginitis:<\/b> (suppository) 200 mg INTRAVAGINALLY at bedtime for 3 days OR 100 mg INTRAVAGINALLY at bedtime for 7 days OR 1200 mg INTRAVAGINALLY once<\/li><li><b>Candidal vulvovaginitis:<\/b> (cream) insert 1 applicatorful (5 g) of 2% cream INTRAVAGINALLY daily for 7 days, or 1 applicatorful (5 g) of 4% cream INTRAVAGINALLY daily for 3 days (guideline dosing)<\/li><li><b>Candidal vulvovaginitis:<\/b> (HIV patients, duration) uncomplicated cases, 3 to 7 days; severe or recurrent, 7 or more days (guideline dosing)<\/li><li><b>Tinea, Superficial:<\/b> apply TOPICALLY to affected areas twice daily<\/li><\/ul>"},"1":{"id":"374290-s-1-5","title":"Pediatric Dosing","mono":"<ul><li><b>Candidal vulvovaginitis:<\/b> 12 yr and older, 200 mg VAGINALLY at bedtime for 3 days<\/li><li><b>Candidal vulvovaginitis:<\/b> 12 yr and older, 100 mg VAGINALLY at bedtime for 7 days<\/li><li><b>Candidal vulvovaginitis:<\/b> 12 yr and older, 1200 mg VAGINALLY once<\/li><li><b>Tinea, Superficial:<\/b> (2 yr and older) apply TOPICALLY to affected areas twice daily<\/li><\/ul>"},"3":{"id":"374290-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Candidal vulvovaginitis<\/li><li>Tinea, Superficial<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><br\/>Diaper rash<br\/>"}}},"3":{"id":"374290-s-3","title":"Contraindications\/Warnings","sub":[{"id":"374290-s-3-9","title":"Contraindications","mono":"specific contraindications have not been determined (vaginal)<br\/>"},{"id":"374290-s-3-10","title":"Precautions","mono":"concomitant use of other vaginal products (eg, tampons, douches, spermicides) not recommended during therapy (vaginal) <br\/>"},{"id":"374290-s-3-11","title":"Pregnancy Category","mono":"<ul><li>Miconazole: C (FDA)<\/li><li>Miconazole: A (AUS)<\/li><\/ul>"},{"id":"374290-s-3-12","title":"Breast Feeding","mono":"<ul><li>Miconazole: WHO: Compatible with breastfeeding.<\/li><li>Miconazole: Micromedex: Infant risk cannot be ruled out.<\/li><\/ul>"}]},"4":{"id":"374290-s-4","title":"Drug Interactions","sub":[{"id":"374290-s-4-13","title":"Contraindicated","mono":"<ul><li>Eletriptan (theoretical)<\/li><li>Pimozide (theoretical)<\/li><\/ul>"},{"id":"374290-s-4-14","title":"Major","mono":"<ul><li>Amiodarone (theoretical)<\/li><li>Apixaban (theoretical)<\/li><li>Cilostazol (theoretical)<\/li><li>Clozapine (established)<\/li><li>Domperidone (theoretical)<\/li><li>Donepezil (theoretical)<\/li><li>Doxorubicin (theoretical)<\/li><li>Doxorubicin Hydrochloride Liposome (theoretical)<\/li><li>Eliglustat (theoretical)<\/li><li>Escitalopram (probable)<\/li><li>Fentanyl (theoretical)<\/li><li>Fosphenytoin (probable)<\/li><li>Glimepiride (theoretical)<\/li><li>Hydrocodone (theoretical)<\/li><li>Ifosfamide (theoretical)<\/li><li>Ivacaftor (theoretical)<\/li><li>Naloxegol (theoretical)<\/li><li>Olaparib (theoretical)<\/li><li>Phenytoin (probable)<\/li><li>Piperaquine (theoretical)<\/li><li>Simeprevir (theoretical)<\/li><li>Warfarin (probable)<\/li><\/ul>"},{"id":"374290-s-4-15","title":"Moderate","mono":"<ul><li>Acenocoumarol (probable)<\/li><li>Anisindione (probable)<\/li><li>Dicumarol (probable)<\/li><li>Oxycodone (established)<\/li><li>Phenprocoumon (probable)<\/li><li>Tolterodine (probable)<\/li><li>Trimetrexate (probable)<\/li><\/ul>"}]},"5":{"id":"374290-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><br\/><b>Dermatologic:<\/b>Contact dermatitis<br\/>"},"6":{"id":"374290-s-6","title":"Drug Name Info","sub":[{"id":"374290-s-6-17","title":"US Trade Names","mono":"<ul><li>Fungoid<\/li><li>Lotrimin AF<\/li><li>Micatin<\/li><li>Monistat 1<\/li><li>Monistat 3<\/li><li>Monistat 7<\/li><li>Zeasorb-AF<\/li><li>Monistat Derm<\/li><\/ul>"},{"id":"374290-s-6-18","title":"Synonyms","mono":"Cleanser<br\/>"},{"id":"374290-s-6-19","title":"Class","mono":"<ul><li>Antifungal<\/li><li>Imidazole<\/li><\/ul>"},{"id":"374290-s-6-20","title":"Regulatory Status","mono":"RX\/OTC<br\/>"},{"id":"374290-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}]},"7":{"id":"374290-s-7","title":"Mechanism Of Action","mono":"Miconazole nitrate, an imidazole antifungal, inhibits biosynthesis of ergosterol in the fungal cell wall membrane. Inhibition of ergosterol allows for accumulation of ergosterol precursors and toxic peroxides which lead to cytolysis of the cell.<br\/>"},"10":{"id":"374290-s-10","title":"Monitoring","mono":"symptomatic improvement <br\/>"},"11":{"id":"374290-s-11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/><ul><li>Topical Cream: 2 %<\/li><li>Topical Ointment: 2 %<\/li><li>Vaginal Cream: 2 %<\/li><li>Vaginal Suppository: 100 MG, 200 MG<\/li><\/ul><\/li><li><b>Aloe Vesta Antifungal<\/b><br\/>Topical Ointment: 2 %<br\/><\/li><li><b>Antifungal<\/b><br\/>Topical Cream: 2 %<br\/><\/li><li><b>Azolen<\/b><br\/>Topical Tincture: 2 %<br\/><\/li><li><b>Baza Antfungal Skin Care Pack<\/b><br\/>Topical Cream: 2 %<br\/><\/li><li><b>Baza Antifungal<\/b><br\/>Topical Cream: 2 %<br\/><\/li><li><b>Critic-Aid Clear AF<\/b><br\/>Topical Ointment: 2 %<br\/><\/li><li><b>Cruex Prescription Strength<\/b><br\/>Topical Spray: 2 %<br\/><\/li><li><b>Derma Gran AF<\/b><br\/>Topical Ointment: 2 %<br\/><\/li><li><b>Desenex<\/b><br\/><ul><li>Topical Powder: 2 %<\/li><li>Topical Spray: 2 %<\/li><\/ul><\/li><li><b>Fungoid<\/b><br\/><ul><li>Topical Kit: 2 %<\/li><li>Topical Tincture: 2 %<\/li><\/ul><\/li><li><b>Good Neighbor Pharmacy Miconazole 7<\/b><br\/>Vaginal Cream: 2 %<br\/><\/li><li><b>Good Neighbor Pharmacy Miconazorb AF<\/b><br\/>Topical Powder: 2 %<br\/><\/li><li><b>Good Sense Miconazole 7<\/b><br\/>Vaginal Cream: 2 %<br\/><\/li><li><b>Leader Miconazole Nitrate<\/b><br\/>Topical Spray: 2 %<br\/><\/li><li><b>Leader Miconazorb AF<\/b><br\/>Topical Powder: 2 %<br\/><\/li><li><b>Lotrimin AF<\/b><br\/><ul><li>Topical Powder: 2 %<\/li><li>Topical Spray: 2 %<\/li><\/ul><\/li><li><b>Micatin<\/b><br\/><ul><li>Topical Cream: 2 %<\/li><li>Topical Powder: 2 %<\/li><li>Topical Spray: 2 %<\/li><\/ul><\/li><li><b>Miconazole 7<\/b><br\/><ul><li>Vaginal Cream: 2 %<\/li><li>Vaginal Suppository: 100 MG<\/li><\/ul><\/li><li><b>Micro-Guard Anti<\/b><br\/>Topical Powder: 2 %<br\/><\/li><li><b>Micro-Guard<\/b><br\/><ul><li>Topical Cream: 2 %<\/li><li>Topical Powder: 2 %<\/li><\/ul><\/li><li><b>Mitrazol<\/b><br\/>Topical Powder: 2 %<br\/><\/li><li><b>Monistat 3<\/b><br\/>Vaginal Suppository: 200 MG<br\/><\/li><li><b>Monistat 7<\/b><br\/>Vaginal Suppository: 100 MG<br\/><\/li><li><b>Quality Choice 3 Day Vaginal<\/b><br\/>Vaginal Cream: 4 %<br\/><\/li><li><b>Quality Choice Miconazole 7<\/b><br\/>Vaginal Cream: 2 %<br\/><\/li><li><b>Remedy Phytoplex<\/b><br\/>Topical Powder: 2 %<br\/><\/li><li><b>Rite Aid Antifungal Cream<\/b><br\/>Topical Cream: 2 %<br\/><\/li><li><b>Rite Aid Foot Care Athlete's Foot Powder Spray<\/b><br\/>Topical Spray: 2 %<br\/><\/li><li><b>Secura Antifungal Extra Thick<\/b><br\/>Topical Cream: 2 %<br\/><\/li><li><b>Secura Antifungal Greaseless<\/b><br\/>Topical Cream: 2 %<br\/><\/li><li><b>Soothe &amp; Cool Free Inzo Antifungal<\/b><br\/>Topical Cream: 2 %<br\/><\/li><li><b>Sunmark Miconazole 7<\/b><br\/>Vaginal Cream: 2 %<br\/><\/li><li><b>Tetterine<\/b><br\/>Topical Ointment: 2 %<br\/><\/li><li><b>TopCare Miconazole 7<\/b><br\/>Vaginal Cream: 2 %<br\/><\/li><li><b>Triple Paste AF<\/b><br\/>Topical Ointment: 2 %<br\/><\/li><li><b>Zeasorb-AF<\/b><br\/><ul><li>Topical Gel\/Jelly: 2 %<\/li><li>Topical Powder: 2 %<\/li><\/ul><\/li><li><b>Zeasorb Antifungal Treatment<\/b><br\/>Topical Powder: 2 %<br\/><\/li><\/ul>"},"12":{"id":"374290-s-12","title":"Toxicology","sub":[{"id":"374290-s-12-31","title":"Clinical Effects","mono":"<b>MICONAZOLE <\/b><br\/>USES: Buccal miconazole tablet is indicated in patients for the local treatment of oropharyngeal candidiasis. Intravaginal miconazole is recommended as an agent of choice for the treatment of vulvovaginal candidiasis. Miconazole 0.25%, zinc oxide 15%, and white petrolatum combination ointment is indicated for the treatment of diaper dermatitis complicated by documented candidiasis. PHARMACOLOGY: Miconazole is an imidazole antifungal agent that inhibits ergosterol synthesis by inhibiting the enzyme CYP450 14-alpha-demethylase. Additionally, miconazole affects triglyceride and fatty acid synthesis and increases the amount of reactive oxygen species within the cell. EPIDEMIOLOGY: Overdose is rare. MILD TO MODERATE TOXICITY: Overdose effects are anticipated to be an extension of adverse effects observed following therapeutic doses. SEVERE TOXICITY: Severe toxicity is not expected after overdose of buccal or topical miconazole. INTRAVENOUS: Seizures have been reported following IV miconazole overdose. Cardiac and respiratory arrest have been observed after high-dose or rapid IV use.  IV formulation is not available in the US. ADVERSE EFFECTS: In general, miconazole is not highly toxic.  Nausea, vomiting, abdominal pain, diarrhea, headache, dysgeusia, pruritus, contact dermatitis, and anaphylactic reactions have been reported following therapeutic use of miconazole. Buccal tablets have also caused oral discomfort, oral burning, oral pain, gingival pain, swelling, or pruritus, tongue ulceration, mouth ulceration, glossodynia, dry mouth, toothache, loss of taste, and altered taste. INTRAVENOUS: Intravenous miconazole has caused tremors, hallucinations, confusion, dizziness, hyponatremia, seizures, transient tachycardia and dysrhythmias, thrombophlebitis, thrombocytosis, microcytic normochromic anemia, phlebitis, and anemia. Intravenous formulation is no longer available in the United States. <br\/>"},{"id":"374290-s-12-32","title":"Treatment","mono":"<b>MICONAZOLE <\/b><br\/><ul><li>Support: MANAGEMENT OF MILD TO MODERATE TOXICITY: Treatment is symptomatic and supportive. Correct any significant fluid and\/or electrolyte abnormalities in patients with vomiting or diarrhea. MANAGEMENT OF SEVERE TOXICITY: Treatment is symptomatic and supportive. Severe toxicity is not expected after overdose of miconazole. In patients with acute allergic reaction, oxygen therapy, bronchodilators, diphenhydramine, corticosteroids, vasopressors, and epinephrine may be required. <\/li><li>Decontamination: PREHOSPITAL:  Prehospital gastrointestinal decontamination is generally not necessary. HOSPITAL: Gastrointestinal decontamination is generally not necessary.<\/li><li>Airway management: Endotracheal intubation and mechanical ventilation may be required in patients with severe allergic reaction.<\/li><li>Antidote: None.<\/li><li>Acute allergic reaction: MILD\/MODERATE: Monitor airway. Administer antihistamines with or without inhaled beta agonists, corticosteroids, or epinephrine. SEVERE: Oxygen, aggressive airway management, antihistamines, epinephrine, corticosteroids, ECG monitoring, and IV fluids.<\/li><li>Monitoring of patient: Routine laboratory studies are not likely to be necessary. Monitor serum electrolytes in patients with severe vomiting and\/or diarrhea.<\/li><li>Enhanced elimination procedure: Hemodialysis is UNLIKELY to be of value because of the high degree of protein binding and low toxicity of miconazole.<\/li><li>Patient disposition: HOME CRITERIA: A patient with an inadvertent ingestion, that remains asymptomatic can be managed at home. OBSERVATION CRITERIA: All patients with deliberate self-harm ingestions should be evaluated in a healthcare facility and monitored until symptoms resolve. ADMISSION CRITERIA: Hospital admission is rarely necessary. Patients should be admitted for severe vomiting, profuse diarrhea, severe abdominal pain, dehydration, and electrolyte abnormalities.  CONSULT CRITERIA: Consult a poison center or medical toxicologist for assistance in managing patients with severe toxicity or in whom the diagnosis is not clear.<\/li><\/ul>"},{"id":"374290-s-12-33","title":"Range of Toxicity","mono":"<b>MICONAZOLE <\/b><br\/>TOXICITY: A toxic dose has not been established. THERAPEUTIC DOSE: BUCCAL: ADULTS: 50 mg buccally once daily for 14 days. CHILDREN: Safety and effectiveness not established in pediatric patients less than 16 yr of age. SUPPOSITORY\/INTRAVAGINAL: ADULTS AND CHILDREN 12 YEARS AND OLDER: 200 mg intravaginally at bedtime for 3 days OR 100 mg intravaginally at bedtime for 7 days OR 1200 mg intravaginally once. <br\/>"}]},"13":{"id":"374290-s-13","title":"Clinical Teaching","mono":"<ul><li>Instruct patient to avoid vaginal intercourse during use of the vaginal preparations.<\/li><li>Patients using vaginal medication should avoid using other vaginal products, such as douches or regular tampons, during therapy.<\/li><\/ul>"}}}